RecruitingPhase 2NCT04941599
2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)
Studying Rare hypercholesterolemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vanderbilt University Medical Center
- Principal Investigator
- MacRae F. Linton, MDVanderbilt University Medical Center
- Intervention
- 2-Hydroxybenzylamine(drug)
- Enrollment
- 72 enrolled
- Eligibility
- 18-69 years · All sexes
- Timeline
- 2024 – 2026
Study locations (1)
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04941599 on ClinicalTrials.govOther trials for Rare hypercholesterolemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07470723The ORIGIN-FH StudyUniversity of Wisconsin, Madison
- RECRUITINGNANCT06960902Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study)Nantes University Hospital
- RECRUITINGPHASE2, PHASE3NCT07058077A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)Merck Sharp & Dohme LLC
- RECRUITINGNCT06958315Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE StudyNovartis Pharmaceuticals
- RECRUITINGNCT04529967Child-Parent Familial Hypercholesterolemia ScreeningChildren's Hospital of Fudan University
- RECRUITINGPHASE3NCT06597006Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial HypercholesterolemiaNovartis Pharmaceuticals
- RECRUITINGNCT06634160Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial HypercholesterolemiaNantes University Hospital
- RECRUITINGPHASE3NCT06597019Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial HypercholesterolemiaNovartis Pharmaceuticals